Data as of Jan 23
| 0.00 / 0.00%|
The 3 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 56.00, with a high estimate of 60.00 and a low estimate of 45.50. The median estimate represents a +41.41% increase from the last price of 39.60.
The current consensus among 3 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.